https://www.thebodypro.com/category/abacavir-epzicom-3tc-kivexa

Abacavir/Lamivudine (Epzicom, Kivexa)

The Latest

Putting test tubes into the holder
News

This Week in HIV Research: I Screen, You Screen, We All Screen for HPV-Related Cancers

May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.

De-Simplifying Single-Tablet Regimens for HIV Treatment Img

De-Simplifying Single-Tablet Regimens for HIV Treatment

A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial Img
Conference Coverage

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial

Once-daily dosing of abacavir (ABC) and lamivudine (3TC) was non-inferior to twice-daily dosing in development of viral resistance in the ARROW trial, according to data presented at the 8th International Workshop on HIV Pediatrics.

IDWeek

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings Img
News

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings

Here's a quick sampling of some of the more noteworthy HIV-related posters presented at a major research conference last week. Topics covered include a surprisingly high frequency of people quitting Atripla due to side effects; the decline of multidr...

News

GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S.

Research Triangle Park -- GlaxoSmithKline \[NYSE: GSK\] announced today the launch of a new Patient Savings Card designed to help eligible patients improve compliance with their HIV regimens by reducing their out-of-pocket expenses for GSK HIV medica...

Conference Coverage

The Once-Daily Abacavir/Lamivudine Co-Formulation Proves Its Mettle by Being Both Safe and Effective

The combination of abacavir (ABC, Ziagen) and lamivudine (3TC, Epivir) is an attractive option as a nucleotide reverse transcriptase inhibitor (NRTI) backbone in antiretroviral therapy, because the combination permits a wide array of future NRTI opti...

Hepatitis C

Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C

How safe are antiretroviral nucleosides in HIV-infected individuals who are coinfected with hepatitis B or hepatitis C? The question is an important one, because of two reasons: Firstly, up to one third of people with HIV are coinfected with hepatiti...

Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine

The combination of abacavir (ABC, Ziagen) and lamivudine (3TC, Epivir), given once daily (QD) or twice daily (BID), or as a fixed-dose combination (FDC), has been extensively studied in antiretroviral-naive patients as part of non-nucleoside reverse ...

Understanding Two New Once-a-Day Combinations: Truvada and Epzicom

Introduction Sexy new drugs have appeared ahead of schedule on drugstore shelves and with much fanfare. Gilead Sciences, gained approval for Truvada, a combination pill of Viread plus Emtriva. GlaxoSmithKline (GSK), have combined Epivir and Ziagen ...